Table 2

Clinicopathological characteristics of patients with BRCA mutationsa No. (%).

Characteristic

BRCA1 mutation (n = 11)

BRCA2 mutation (n = 43)

BRCA1 and BRCA2 mutation (n = 36)

P Valueb

Age≥65y

0.040

No

3 (30.0)

26 (60.5)

26 (74.3)

Yes

7 (70.0)

17 (39.5)

9 (25.7)

BMI≥28 kg/m2

0.025

No

1 (11.1)

15 (35.7)

19 (57.6)

Yes

8 (88.9)

27 (64.3)

14 (42.4)

Diabetes history

0.911

No

5 (71.4)

24 (77.4)

21 (80.8)

Yes

2 (28.6)

7 (22.6)

5 (19.2)

Hypertension history

0.162

No

2 (25.0)

16 (47.1)

19 (61.3)

Yes

6 (75.0)

18 (52.9)

12 (38.7)

AJCC stage

0.087

Early (stage I-II)

8 (72.7)

38 (88.4)

25 (69.4)

Advanced (stage III-IV)

3 (27.3)

5 (11.6)

11 (30.6)

Grade

<0.001

Low (G1 - 2)

3 (27.3)

26 (60.5)

7 (19.4)

High (G3)

8 (72.7)

17 (39.5)

29 (80.6)

Histology

0.181

Endometrioid type

8 (72.7)

40 (93.0)

32 (88.9)

Non-endometrioid type

3 (27.3)

3 (7.0)

4 (11.1)

Lymph node metastasis

0.017

No

7 (77.8)

38 (97.4)

24 (77.4)

Yes

2 (22.2)

1 (2.6)

7 (22.6)

Depth of myometrial invasion

0.462

<50%

3 (42.9)

25 (62.5)

16 (50.0)

≥50%

4 (57.1)

15 (37.5)

16 (50.0)

Peritoneal cytology

0.713

Negative

7 (100.0)

31 (96.9)

27 (93.1)

Positive

0

1 (3.1)

2 (6.9)

Residual disease

0.024

No

4 (57.1)

26 (76.5)

30 (93.8)

Yes

3 (42.9)

8 (23.5)

2 (6.3)

Radiation therapy use

0.904

No

5 (55.6)

25 (59.5)

19 (52.8)

Yes

4 (44.4)

17 (40.5)

17 (47.2)

Chemotherapy use

0.731

No

3 (60.0)

14 (66.7)

15 (75.0)

Yes

2 (40.0)

7 (33.3)

5 (25.0)

Molecular targeted therapy use

0.256

No

4 (80.0)

27 (81.8)

17 (63.0)

Yes

1 (20.0)

6 (18.2)

10 (37.0)

  • Abbreviations: BMI, body mass index; AJCC, American Joint Committee on Cancer.

  • a For some characteristics, the values do not sum to heading totals because of missing data.

  • b Fisher's exact test.